WFD Ventures

WFD Ventures

WFD Ventures was founded in 2002 and operates from New York, deploying capital exclusively in early-to-growth stage medical technology companies. The firm is led by Managing Partner Yumin Choi, who has steered its sector-focused strategy for over two decades. The firm does not disclose wealth origin or outside capital partners. The firm invests across medical devices, diagnostics, digital health, and therapeutic platforms, typically entering at Seed through Series B rounds with initial checks under $10 million. WFD reserves significant reserves for follow-on, often staying with portfolio companies through commercialization and regulatory clearance. Confirmed positions include TransMedics, the organ preservation and transport platform that went public in 2019, and CardioMEMS, the implantable heart failure monitor acquired by Abbott (per the firms' public filings). Geographic focus centers on the United States, with limited exposure to EU early-stage medtech. WFD Ventures maintains a concentrated portfolio built around a small team. The firm raised WFD Ventures VI, disclosed in SEC filings from 2022, consistent with its pattern of sub-$200 million funds. The firm does not operate adjacent vehicles or a philanthropic foundation under the WFD brand. In March 2024, WFD marked a portfolio milestone when TransMedics reported its first full year of GAAP profitability, a rare event for a company the firm backed at Series A (per TransMedics Q4 2023 earnings, March 2024). WFD's structural edge is its clinical-specialist identity inside a generalist-dominated venture market. The firm competes for deals not on check size but on therapeutic-area fluency — a posture that lets it co-invest alongside strategics like Johnson & Johnson Development Corporation and gain access to academic spinouts from institutions including the Cleveland Clinic and Massachusetts General Hospital that prefer domain-expert lead investors.